Abstract:Background Fibroblast growth factor 21 (FGF21), a glucose and lipid metabolic regulator, has recently been demonstrated to be associated with cardiovascular diseases (CVD) such as carotid atherosclerosis, coronary heart disease and carotid artery plaques. However, the relationship between circulating FGF21 and subclinical atherosclerosis or atherosclerosis of other arteries such as the femoral and iliac artery remains unclear. In this study, we evaluated the association of serum FGF21 with intima-media thickness (IMT) and subclinical atherosclerosis in type 2 diabetic patients. Methods Serum FGF21 levels were detected by enzyme-linked immunosorbent assay in 212 newly diagnosed type 2 diabetic patients without clinical symptoms of atherosclerosis or cardiovascular diseases. IMT of the carotid, femoral, and iliac arteries were measured by high-resolution B-mode ultrasound to determine the presence of subclinical atherosclerosis, which was defined as having an IMT > 1.0 mm and/or plaque on one or more of the three arteries without any clinical manifestations. The relationship between serum FGF21 levels and subclinical atherosclerosis was analyzed. Results Serum FGF21 levels were significantly higher in patients with subclinical atherosclerosis compared to those without [261.3 (135.1–396.4) versus 144.9 (95.9–223.0) ng/L, P < 0.001]. These differences were also observed in both men and women with subclinical atherosclerosis compared to their respective groups without [men: 243.2 (107.6–337.0) versus 136.8 (83.6–212.8) ng/L, P = 0.048; women: 292.4 (174.2–419.9) versus 160.4 (115.3–258.5) ng/L, P = 0.001]. Moreover, serum FGF21 levels showed a significantly positive correlation with carotid IMT in women (r = 0.23, P = 0.018) and with iliac IMT in both genders (women: r = 0.27, P = 0.005; men: r = 0.22, P = 0.024). Multiple logistic regression analysis further showed that serum FGF21 was an independent impact factor for subclinical atherosclerosis in patients with type 2 diabetes. Conclusions Serum FGF21 is elevated in newly diagnosed type 2 diabetes, and positively correlates with carotid and iliac lesions in patients with subclinical atherosclerosis, especially in women. High levels of FGF21 may be a compensatory reaction to offset atherosclerosis.

Changes of serum fibroblast growth factor 21 in people with different fasting plasma glucose and its correlation with glycolipid metabolism

Change and Clinical Significance of Serum Fibroblast Growth Factor 21 Levels in Type 2 Diabetic Patients

High circulating fibroblast growth factor-21 levels as a screening marker in fatty pancreas patients

High Circulating Fibroblast Growth Factor-21 Levels as a Prognostic Marker in Fatty Pancreas Patients

Serum FGF-21 levels in type 2 diabetic patients.

Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and Without Type 2 Diabetes

Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging.

Relationship between serum FGF -19, FGF -21 levels and insulin resistance in women with gestational diabetes mellitus

Distinct Changes in Serum Fibroblast Growth Factor 21 Levels in Different Subtypes of Diabetes.

Serum Fibroblast Growth Factor 21 is Associated with Adverse Lipid Profiles and Gamma-Glutamyltransferase but Not Insulin Sensitivity in Chinese Subjects

Elevated Fibroblast Growth Factor-21 Protect Endothelial Function in Type 2 Diabetes Patients

Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently.

Serum Fibroblast Growth Factor 19 Levels Are Decreased in Chinese Subjects With Impaired Fasting Glucose and Inversely Associated With Fasting Plasma Glucose Levels

Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes.

Association of serum fibroblast growth factor 21 and urinary glucose excretion in hospitalized patients with type 2 diabetes

Association Between Serum Fibroblast Growth Factor 21 and Diabetic Nephropathy.

Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes

Decreased levels of Fibroblast Growth Factor 21 are correlated with improved hypoglycemia in patients with insulinoma

Association of serum fibroblast growth factor 21 with kidney function in a population-based Chinese cohort

High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects.

Decreased Serum Fibroblast Growth Factor 19 Level is a Risk Factor for Type 1 Diabetes